Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate scPharmaceuticals Inc. before investing.

In this article, we go over a few key elements for understanding scPharmaceuticals Inc.’s stock price such as:

• scPharmaceuticals Inc.’s current stock price and volume
• Why scPharmaceuticals Inc.’s stock price changed recently
• Upgrades and downgrades for SCPH from analysts
• SCPH’s stock price momentum as measured by its relative strength

About scPharmaceuticals Inc. (SCPH)

Before we jump into scPharmaceuticals Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

scPharmaceuticals Inc., a pharmaceutical company, focuses on developing and commercializing products to optimize the delivery of infused therapies and patient care. The company’s lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for the treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. Its product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity and drug-device combination product candidate consisting of a prefilled syringe containing SCP-111 preloaded into a mechanical autoinjector. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

Want to learn more about scPharmaceuticals Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about scPharmaceuticals Inc..

scPharmaceuticals Inc.’s Stock Price as of Market Close

As of May 15, 2025, 12:32 PM, CST, scPharmaceuticals Inc.’s stock price was $2.800.

scPharmaceuticals Inc. is up 25% from its previous closing price of $2.240.

During the last market session, scPharmaceuticals Inc.’s stock traded between $2.200 and $2.870. Currently, there are approximately 53.46 million shares outstanding for scPharmaceuticals Inc..

scPharmaceuticals Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

scPharmaceuticals Inc. Stock Price History

scPharmaceuticals Inc.’s (SCPH) price is currently up 9.8% so far this month.

During the month of May, scPharmaceuticals Inc.’s stock price has reached a high of $2.870 and a low of $2.200.

Over the last year, scPharmaceuticals Inc. has hit prices as high as $5.650 and as low as $1.940. Year to date, scPharmaceuticals Inc.’s stock is down 20.9%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused scPharmaceuticals Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of May 14, 2025,, no analysts have changed their rating of scPharmaceuticals Inc.’s stock over the last month.

Additionally, you'll want to evaluate scPharmaceuticals Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on scPharmaceuticals Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

scPharmaceuticals Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about scPharmaceuticals Inc. (SCPH) by visiting AAII Stock Evaluator.

Relative Price Strength of scPharmaceuticals Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 14, 2025, scPharmaceuticals Inc. has a weighted four-quarter relative price strength of -20.30%, which translates to a Momentum Score of 11 and is considered to be Very Weak.

Want to learn more about how scPharmaceuticals Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

scPharmaceuticals Inc. Stock Price: Bottom Line

As of May 15, 2025, scPharmaceuticals Inc.’s stock price is $2.800, which is up 25% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like scPharmaceuticals Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.